We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




AI Algorithm Listens To Patients Pass Urine for Assessing Urinary Tract Symptoms

By LabMedica International staff writers
Posted on 05 Jul 2022
Print article
Image: Machine learning goes with the flow (Photo courtesy of Pexels)
Image: Machine learning goes with the flow (Photo courtesy of Pexels)

Lower urinary tract symptoms, problems related to the working of the bladder and the urethra, are common and affect an estimated 60% of men and 57% of women. Uroflowmetry is an important tool for the assessment of patients with symptoms, but patients have to urinate into a machine during outpatient visits. They are asked to urinate into a funnel connected to the uroflowmeter which records information about flow. During the COVID-19 pandemic access to clinics has been restricted, and even where patients can attend, the test can take a long time with queues to use a single machine. Now, an artificial intelligence (AI) algorithm trained to listen to patients pass urine can identify abnormal flows and could be a useful and cost-effective means of monitoring and managing urology patients at home.

The deep learning tool, Audioflow, that was developed by researchers at the Singapore General Hospital (Singapore) performed almost as well as a specialist machine used in clinics, and achieved similar results to urology residents in assessing urinary flow. The current study focused on sound created by urine in a soundproof environment, but the ambition is to create an app so patients can monitor themselves at home. In order to train and validate the algorithm, the researchers recruited 534 male participants between December 2017 and July 2019 to it. Participants used the usual uroflowmetry machine in a soundproofed room, and recorded their urination using a smartphone.

Using 220 recordings, the AI learned to estimate flow rate, volume, and time which can indicate when there is an obstruction or if the bladder is not working well. It was trained to listen to and analyze male urinary flow which is different from that of women and would need a separate sample to learn to analyze female urination. The results were compared to a conventional uroflowmetry machine and to a panel of six urology residents who separately graded the dataset. The AI agreed with conventional uroflowmetry for over 80% of recordings, and compared to the specialist urologists and external residents for identification of abnormal flows, it achieved an 84% rate of agreement. Audioflow will now be rolled out as a smartphone app via primary care physicians so it can be tested in the real world and learn from different datasets in different noise environments.

“There is a trend towards using machine learning in many fields, because clinicians do not have a lot of time. At the same time, particularly since the pandemic there is a shift towards telemedicine and less hospital-based care. We were keen to develop a way to monitor our patients to see how they are doing between hospital visits,” said Dr. Lee Han Jie from the Singapore General Hospital who led the development of the algorithm. “Our AI can outperform some non-experts and comes close to senior consultants. But the real benefit is having the equivalent of a consultant in the bathroom with you, every time you go. We are now working towards the algorithm being able to work when there is background noise in the normal home environment and this will make the true difference for patients.”

“Giving patients the ability to measure urinary flow at home is more comfortable for them and reduces time waiting in the clinic,” said Christian Gratzke, Professor of Urology at University Hospital Freiburg and member of the EAU22 Scientific Congress Committee of Urology. “This is a well-executed study with a significant number of patients and represents a promising approach to developing a portable app that can be used at home. I look forward to seeing the real-world results.”

Related Links:
Singapore General Hospital

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.